GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model

Biochemical and Biophysical Research Communications

Volumn 423, Issue 2, 2012, Pages 295-300

  Nishizawa, Hitoshi ^a   Takahashi, Michiko ^a   Fukuoka, Hidenori ^a   Iguchi, Genzo ^a   Kitazawa, Riko ^b   Takahashi, Yutaka ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adult growth hormone deficiency; GH; IGF I; Mitochondria; NAFLD; NASH; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL FUNCTION; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; GROWTH HORMONE DEFICIENCY; HUMAN; LIVER CELL; LIVER FIBROSIS; MALE; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; DISEASE MODELS, ANIMAL; FATTY LIVER; GROWTH HORMONE; HEPATOCYTES; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; MITOCHONDRIA, LIVER; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84862902026     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.115     Document Type: Article

References (33)

1. Smith B.W., Adams L.A. Non-alcoholic fatty liver disease. Crit. Rev. Clin. Lab Sci. 2011, 48:97-113.
2. Adams L.A., Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet. Med. 2005, 22:1129-1133.
3. Loria P., Carulli L., Bertolotti M., Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:236-247.
4. Adams L.A., Feldstein A., Lindor K.D., Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004, 39:909-914.
5. Thomas J.D., Monson J.P. Adult GH deficiency throughout lifetime. Eur. J. Endocrinol. 2009, 161(Suppl. 1):S97-S106.
6. Ichikawa T., Hamasaki K., Ishikawa H., Ejima E., Eguchi K., Nakao K. Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 2003, 52:914.
7. Takahashi Y., Iida K., Takahashi K., Yoshioka S., Fukuoka H., Takeno R., Imanaka M., Nishizawa H., Takahashi M., Seo Y., Hayashi Y., Kondo T., Okimura Y., Kaji H., Kitazawa R., Kitazawa S., Chihara K. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology 2007, 132:938-943.
8. H. Nishizawa, G. Iguchi, A. Murawaki, H. Fukuoka, Y. Hayashi, H. Kaji, M. Yamamoto, K. Suda, M. Takahashi, Y. Seo, Y. Yano, R. Kitazawa, S. Kitazawa, M. Koga, Y. Okimura, K. Chihara, Y. Takahashi, Nonalcoholic fatty liver disease in adult hypopituitary patients with growth hormone deficiency and the impact of growth hormone replacement therapy, Eur. J. Endocrinol. (2012) Apr 24. (Epub ahead of print).
9. Fan Y., Menon R.K., Cohen P., Hwang D., Clemens T., DiGirolamo D.J., Kopchick J.J., Le Roith D., Trucco M., Sperling M.A. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J. Biol. Chem. 2009, 284:19937-19944.
10. Sos B.C., Harris C., Nordstrom S.M., Tran J.L., Balazs M., Caplazi P., Febbraio M., Applegate M.A., Wagner K.U., Weiss E.J. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J. Clin. Invest. 2011, 121:1412-1423.
11. Cui Y., Hosui A., Sun R., Shen K., Gavrilova O., Chen W., Cam M.C., Gao B., Robinson G.W., Hennighausen L. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology 2007, 46:504-513.
12. Barclay J.L., Nelson C.N., Ishikawa M., Murray L.A., Kerr L.M., McPhee T.R., Powell E.E., Waters M.J. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 2011, 152:181-192.
13. Sobrevals L., Rodriguez C., Romero-Trevejo J.L., Gondi G., Monreal I., Paneda A., Juanarena N., Arcelus S., Razquin N., Guembe L., Gonzalez-Aseguinolaza G., Prieto J., Fortes P. Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 2010, 51:912-921.
14. Gravholt C.H., Schmitz O., Simonsen L., Bulow J., Christiansen J.S., Moller N. Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am. J. Physiol. 1999, 277:E848-E854.
15. Kamegai J., Unterman T.G., Frohman L.A., Kineman R.D. Hypothalamic/pituitary-axis of the spontaneous dwarf rat: autofeedback regulation of growth hormone (GH) includes suppression of GH releasing-hormone receptor messenger ribonucleic acid. Endocrinology 1998, 139:3554-3560.
16. Krizhanovsky V., Yon M., Dickins R.A., Hearn S., Simon J., Miething C., Yee H., Zender L., Lowe S.W. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134:657-667.
17. Takahashi M., Okimura Y., Iguchi G., Nishizawa H., Yamamoto M., Suda K., Kitazawa R., Fujimoto W., Takahashi K., Zolotaryov F.N., Hong K.S., Kiyonari H., Abe T., Kaji H., Kitazawa S., Kasuga M., Chihara K., Takahashi Y. Chemerin regulates beta-cell function in mice. Sci. Rep. 2011, 1:123.
18. Takahashi Y., Iida K., Takeno R., Kitazawa R., Kitazawa S., Kitamura H., Fujioka Y., Yamada H., Kanda F., Ohta S., Nishimaki K., Fujimoto M., Kondo T., Iguchi G., Takahashi K., Kaji H., Okimura Y., Chihara K. Hepatic failure and enhanced oxidative stress in mitochondrial diabetes. Endocr. J. 2008, 55:509-514.
19. Takeuchi T., Suzuki H., Sakurai S., Nogami H., Okuma S., Ishikawa H. Molecular mechanism of growth hormone (GH) deficiency in the spontaneous dwarf rat: detection of abnormal splicing of GH messenger ribonucleic acid by the polymerase chain reaction. Endocrinology 1990, 126:31-38.
20. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biol. Med. 2012, 52:59-69.
21. Perez R., Garcia-Fernandez M., Diaz-Sanchez M., Puche J.E., Delgado G., Conchillo M., Muntane J., Castilla-Cortazar I. Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis. World J. Gastroenterol. 2008, 14:2731-2739.
22. Puche J.E., Garcia-Fernandez M., Muntane J., Rioja J., Gonzalez-Baron S., Castilla Cortazar I. Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology 2008, 149:2620-2627.
23. Arturi F., Succurro E., Procopio C., Pedace E., Mannino G.C., Lugara M., Procopio T., Andreozzi F., Sciacqua A., Hribal M.L., Perticone F., Sesti G. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J. Clin. Endocrinol. Metab. 2011, 96:E1640-E1644.
24. Volzke H., Aumann N., Krebs A., Nauck M., Steveling A., Lerch M.M., Rosskopf D., Wallaschofski H. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int. J. Androl. 2010, 33:45-53.
25. Garcia-Galiano D., Sanchez-Garrido M.A., Espejo I., Montero J.L., Costan G., Marchal T., Membrives A., Gallardo-Valverde J.M., Munoz-Castaneda J.R., Arevalo E., De la Mata M., Muntane J. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes. Surg. 2007, 17:493-503.
26. Ichikawa T., Nakao K., Hamasaki K., Furukawa R., Tsuruta S., Ueda Y., Taura N., Shibata H., Fujimoto M., Toriyama K., Eguchi K. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol. Int. 2007, 1:287-294.
27. Tateno C., Kataoka M., Utoh R., Tachibana A., Itamoto T., Asahara T., Miya F., Tsunoda T., Yoshizato K. Growth hormone-dependent pathogenesis of human hepatic steatosis in a novel mouse model bearing a human hepatocyte-repopulated liver. Endocrinology 2011, 152:1479-1491.
28. Hao C.N., Geng Y.J., Li F., Yang T., Su D.F., Duan J.L., Li Y. Insulin-like growth factor-1 receptor activation prevents hydrogen peroxide-induced oxidative stress, mitochondrial dysfunction and apoptosis. Apoptosis 2011, 16:1118-1127.
29. Yakar S., Liu J.L., Fernandez A.M., Wu Y., Schally A.V., Frystyk J., Chernausek S.D., Mejia W., Le Roith D. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001, 50:1110-1118.
30. Conchillo M., de Knegt R.J., Payeras M., Quiroga J., Sangro B., Herrero J.I., Castilla-Cortazar I., Frystyk J., Flyvbjerg A., Yoshizawa C., Jansen P.L., Scharschmidt B., Prieto J. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J. Hepatol. 2005, 43:630-636.
31. Yakar S., Liu J.L., Stannard B., Butler A., Accili D., Sauer B., LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7324-7329.
32. Volzke H., Nauck M., Rettig R., Dorr M., Higham C., Brabant G., Wallaschofski H. Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur. J. Endocrinol. 2009, 161:705-713.
33. Bonefeld K., Moller S. Insulin-like growth factor-I and the liver. Liver Int. 2011, 31:911-919.